212 related articles for article (PubMed ID: 36632151)
41.
Fassbind S; Ferraro DA; Stelmes JJ; Fankhauser CD; Guckenberger M; Kaufmann PA; Eberli D; Burger IA; Kranzbühler B
Ann Nucl Med; 2021 Oct; 35(10):1109-1116. PubMed ID: 34185262
[TBL] [Abstract][Full Text] [Related]
42. [COST ANALYSIS OF ANDROGEN DEPRIVATION THERAPY AND DRUGS FOR CASTRATION-RESISTANT PROSTATE CANCER].
Nishizawa K; Hattahara K; Onishi H; Yoshida T
Nihon Hinyokika Gakkai Zasshi; 2021; 112(2):53-57. PubMed ID: 35444081
[TBL] [Abstract][Full Text] [Related]
43. Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)-a prospective single-arm interventional study.
Sugimoto M; Kato T; Tohi Y; Shimizu Y; Matsumoto R; Inoue T; Takezawa Y; Masui K; Sasaki H; Hirama H; Saito S; Egawa S; Kamoto T; Teramukai S; Kojima S; Kikuchi T; Kakehi Y
BMC Urol; 2022 Sep; 22(1):151. PubMed ID: 36104667
[TBL] [Abstract][Full Text] [Related]
44. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.
Fendler WP; Weber M; Iravani A; Hofman MS; Calais J; Czernin J; Ilhan H; Saad F; Small EJ; Smith MR; Perez PM; Hope TA; Rauscher I; Londhe A; Lopez-Gitlitz A; Cheng S; Maurer T; Herrmann K; Eiber M; Hadaschik B
Clin Cancer Res; 2019 Dec; 25(24):7448-7454. PubMed ID: 31511295
[TBL] [Abstract][Full Text] [Related]
45. Prostate cancer management in Southeast Asian countries: a survey of clinical practice patterns.
Chiong E; Saad M; Hamid ARAH; Ong-Cornel AB; Lojanapiwat B; Pripatnanont C; Serrano D; Songco J; Sin LC; Hakim L; Chua MLK; Nguyen NP; Phuong PC; Patnaik RS; Umbas R; Kanesvaran R
Ther Adv Med Oncol; 2024; 16():17588359231216582. PubMed ID: 38249332
[TBL] [Abstract][Full Text] [Related]
46. Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2.
Bryce AH; Crawford ED; Agarwal N; Hussain MH; Beltran H; Cooperberg MR; Petrylak DP; Shore N; Spratt DE; Tagawa ST; Antonarakis ES; Aparicio AM; Armstrong AJ; Boike TP; Calais J; Carducci MA; Chapin BF; Cookson MS; Davis JW; Dorff T; Eggener SE; Feng FY; Gleave M; Higano C; Iagaru A; Morgans AK; Morris M; Murray KS; Poage W; Rettig MB; Sartor O; Scher HI; Sieber P; Small E; Srinivas S; Yu EY; Zhang T; Koo PJ
JU Open Plus; 2024 Apr; 2(4):. PubMed ID: 38774467
[TBL] [Abstract][Full Text] [Related]
47. Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases.
Takahashi S; Kinuya S; Nonomura N; Shinohara N; Suzuki K; Suzuki H; Nakamura K; Satoh T; Tateishi U; Yoneda T; Horikoshi H; Igawa T; Kamai T; Koizumi M; Kosaka T; Matsubara N; Miyake H; Mizokami A; Mizowaki T; Nakamura N; Nozawa M; Takahashi T; Uemura H; Uemura M; Yokomizo A; Yoshimura M; Kakehi Y
Oncol Ther; 2018 Dec; 6(2):157-171. PubMed ID: 32700033
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study.
Li JR; Wang SS; Chen CS; Yang CK; Lu K; Cheng CL; Hung SC; Chen SY; Hsu CY; Chiu KY
Anticancer Res; 2022 Oct; 42(10):4857-4866. PubMed ID: 36191989
[TBL] [Abstract][Full Text] [Related]
49. Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation.
Bergamini M; Dalla Volta A; Caramella I; Bercich L; Fisogni S; Bertoli M; Valcamonico F; Grisanti S; Poliani PL; Bertagna F; Berruti A
Front Oncol; 2022; 12():937713. PubMed ID: 35936689
[TBL] [Abstract][Full Text] [Related]
50. [Prostate-specific membrane antigen positron emission tomography (PSMA PET) for urologists-when and which tracer?].
Berliner C; Kesch C; Fendler WP; Eiber M; Maurer T
Urologe A; 2022 Apr; 61(4):384-391. PubMed ID: 35138414
[TBL] [Abstract][Full Text] [Related]
51. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [
Fanti S; Briganti A; Emmett L; Fizazi K; Gillessen S; Goffin K; Hadaschik BA; Herrmann K; Kunikowska J; Maurer T; MacLennan S; Mottet N; Murphy DG; Oprea-Lager DE; O'Sullivan JM; Oyen WJG; Rouvière O; Sartor O; Stenzl A; Van Poppel H; Walz J; Witjes W; Bjartell A
Eur Urol Oncol; 2022 Oct; 5(5):530-536. PubMed ID: 35697600
[TBL] [Abstract][Full Text] [Related]
52. Stereotactic Radiotherapy for Lesions Detected via
Pan J; Wei Y; Zhang T; Liu C; Hu X; Zhao J; Gan H; Liu W; Zhu B; Wu J; Wang B; Song S; Ye D; Zhu Y
Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107
[TBL] [Abstract][Full Text] [Related]
53. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG
Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328
[TBL] [Abstract][Full Text] [Related]
54. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
55. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
Lohaus F; Zöphel K; Löck S; Wirth M; Kotzerke J; Krause M; Baumann M; Troost EGC; Hölscher T
Eur Urol; 2019 Apr; 75(4):548-551. PubMed ID: 30578119
[TBL] [Abstract][Full Text] [Related]
56. Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer.
Vlachostergios PJ; Niaz MJ; Sun M; Mosallaie SA; Thomas C; Christos PJ; Osborne JR; Molina AM; Nanus DM; Bander NH; Tagawa ST
Front Oncol; 2021; 11():630589. PubMed ID: 33680970
[TBL] [Abstract][Full Text] [Related]
57. Addressing controversial areas in the management of advanced prostate cancer in Canada Areas of consensus and controversy from the third Canadian consensus forum.
Saad F; Hotte SJ; Noonan K; Malone S; Morash C; Niazi T; Rendon RA; Shayegan B; Basappa NS; Cagiannos I; Danielson B; Delouya G; Fernandes R; Ferrario C; Finelli A; Gotto GT; Hamilton RJ; Izard JP; Kapoor A; Lalani AK; Lavallée LT; Ong M; Pouliot F; So AI; Yip S; Chi KN
Can Urol Assoc J; 2024 Apr; 18(4):E127-E137. PubMed ID: 38381937
[TBL] [Abstract][Full Text] [Related]
58. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
59. Prostate-specific membrane antigen (PSMA)-based imaging in localized and advanced prostate cancer: a narrative review.
de Kouchkovsky I; Aggarwal R; Hope TA
Transl Androl Urol; 2021 Jul; 10(7):3130-3143. PubMed ID: 34430416
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
